Barely Significant
← all phrases

“a nonsignificant trend”

5,407 sentences · 5,407 papers · 7,516 search hits before verification · confirmed specimen

Sighted at

p<0.1

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

In the subgroup without CKD at baseline, a nonsignificant trend was observed for the prespecified end-point of a 30% reduction in eGFR (measured twice ≥90 days apart) to an eGFR < 60 ml/min per 1.73 m 2 , initiation of dialysis, or kidney transplantation (HR = 1.64, 95% CI = 0.85−2.93, P = 0.114 recessive model), but not for incident proteinuria.
Effect of PET scanning on appropriate decision showed a nonsignificant trend towards a reduction in the predefined composite endpoint (cardiac death, myocardial infarction, or cardiac rehospitalization) at one year (Hazard Ratio 0.78, 95% CI 0.58 to 1.1; p = 0.15), with post hoc analysis showing a statistically significant reduction in adverse events in the FDG PET-assisted group (Hazard Ratio 0.62, 95% CI 0.42 to 0.93; p = 0.019) [ 58 ].
concluded that more clinically complex patients have a nonsignificant trend toward a higher rate of single positive findings. 3 Karaca et al. found that many cases of presumed phenotypic expansion are actually patients with multiple Mendelian conditions. 2 Posey et al. used Human Phenotype Ontology (HPO) terms to determine the degree of phenotypic overlap of individual patients’ dual diagnoses. 4 To our knowledge, however, this study is the first to compare clinical complexity between patients with single and multiple potentially relevant findings.
20 This led to a phase II randomized trial with guadecitabine plus carboplatin compared to physician choice that showed a nonsignificant trend for improvement in overall PFS (16.3 weeks vs. 9.1 weeks). 21 However, the 6‐month PFS was significantly higher in the guadecitabine plus carboplatin group (37% vs. 11%, p = 0.003), validating the potential utility of HMAs as re‐sensitization agents. 21 A phase I study also demonstrated early promising results for the use of guadecitabine plus irinotecan in metastatic colon cancer. 42 The MTD of our trial was determined to be 30 mg/m 2 guadecitabine day 1 through day 5 and 100 mg/m 2 cisplatin on day 8 of a 28‐day cycle.
There was a nonsignificant trend toward increased baseline spine elimination rate in MECP2 -duplication mice versus littermate controls across the 8 d of imaging ( Fig. 1 I , J ), although our study was not statistically powered to detect this difference given variability in WT animals (1−β = 0.60 for d1→5; 1−β = 0.64 for d5→9).